Sumitomo Dainippon Pharma, Poxel Ink $300M Diabetes Pact Post author:Sam Post published:October 29, 2017 Post category:BioPharma The two companies will jointly develop Imeglimin for the treatment of type 2 diabetes in Japan. Source: BioSpace You Might Also Like Why Investors Should Dodge Gilead in 2018 December 28, 2017 Ionis and Roche Tout Positive Data in Early-Stage Huntington’s Disease Trial March 1, 2018 Germany's Fresenius Kabi AG Slams Down $4.3 Billion for Akorn in U.S. Expansion April 24, 2017